

paconiflorin, quercitrin, rutin, swertiamarin, terpineol, trans-cinnamaldehyde, trans-cinnamic acid, umbelliferone, genkwanin, homoorientin, isovitexin, neohesperidin, wongonin, capillarisin, liquiritin, ethyl myristate, poncirin, and ursolic acid.

Amended
(Please amend claim 2 as follows:)

Claim 2. (Once Amended). The dermal cytochrome P450 1A (CYP1A) inhibitor according to claim 1, wherein said dermal CYP1A inhibitor is a compound selected from the group consisting of kaempferol, luteolin-7-glycoside, terpineol, α -naphthoflavone, β -naphthoflavone, and hesperetin.

Please cancel claims 3-9.

Please add new claims 17-26 as follows:

Q2 New Claim 17. A pharmaceutical composition comprising a free base or pharmaceutically acceptable salt of at least one of the dermal CYP1A inhibitor according to claim 1.

New Claim 18. The pharmaceutical composition according to claim 17, wherein said pharmaceutical composition inhibits cytochrome P450 1A enzymatic activity.

New Claim 19. The pharmaceutical composition according to claim 17, wherein said pharmaceutical composition is topically administered to a mammal.

New Claim 20. The pharmaceutical composition according to claim 18, wherein said cytochrome P450 1A enzymatic activity is a first-pass metabolism of a drug.

New Claim 21. The pharmaceutical composition according to claim 20, wherein said drug is a dermatological drug.

New Claim 22. The pharmaceutical composition according to claim 21, wherein said dermatological drug is retinoid.

New Claim 23. The pharmaceutical composition according to claim 21, wherein said dermatological drug is retinoic acid.

New Claim 24. The pharmaceutical composition according to claim 21, wherein said dermatological drug is topically co-administered with said pharmaceutical composition to a mammal.

New Claim 25. The pharmaceutical composition according to claim 18, wherein said cytochrome 450 1A enzymatic activity converts a chemical into a carcinogen.

New Claim 26. The pharmaceutical composition according to claim 25, wherein said carcinogen causes skin cancer in a mammal.

REMARKS

Applicants request favorable reconsideration of the subject application in view of the amendments and the following remarks.

In the Office Action dated December 18, 2002, claims 3-4 and 8-9 were objected to under 37 C.F.R. §1.75(c) as being of improper dependent form; claims 1-9 were rejected under 35 U.S.C. §112, second paragraph, as being indefinite; claims 1, 3-6, and 8-9 were rejected under 35 U.S.C. §102(b) as being anticipated by Burger et al., U.S. Patent 5,665,367 (the Burger reference). Applicants also acknowledge safe receipt of the "Notice of References Cited" (form PTO-892) and the attached references.